Home/Pipeline/BRAVYL (oral fasudil)

BRAVYL (oral fasudil)

Amyotrophic Lateral Sclerosis (ALS)

Phase 2a completedActive

Key Facts

Indication

Amyotrophic Lateral Sclerosis (ALS)

Phase

Phase 2a completed

Status

Active

Company

Woolsey Pharmaceuticals

About Woolsey Pharmaceuticals

Woolsey Pharmaceuticals is a private, pre-revenue biotech company targeting high-need neurodegenerative diseases, with ALS as its lead indication. The company's most advanced asset is BRAVYL (oral fasudil), a Rho kinase inhibitor, which has completed a Phase 2a study in ALS patients, showing promising biomarker data. While initially described as operating in oncology and rare disease, the website content reveals a sharp, current focus on neurodegenerative disorders, positioning the company in a challenging but critically important therapeutic area with significant unmet medical need.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Rare Disease

Other Amyotrophic Lateral Sclerosis (ALS) Drugs

Drug	Company	Phase	Status
NPT520-34	Neuropore Therapies	Pre-clinical/Phase 1	Partnered (Biogen), Active
NUZ-001	Neurizon Therapeutics	Phase 2/3 (Platform Trial)	Active
CNM-Au8	Clene	Phase 2/3	Active
Masitinib	AB Science	Phase 3	Active
Undisclosed Program	Zhimeng Biopharma	Clinical	Active
SLS-005	Seelos Therapeutics	Platform Trial	Active (HEALEY ALS Platform Trial – Regimen E)
PMN442	ProMIS Neurosciences	Preclinical	Active
nAV-101	nVector	Pre-clinical	Active
ALTA-808	Alteron Therapeutics	Preclinical	IND-enabling studies launching
GM6	Genervon Biopharmaceuticals	Phase 2	Active
Lou Gehrig’s disease	Genclis	Discovery	Active
Treg-directed therapy for ALS	Iltoo Pharma	Pre-clinical	Active